The Disciplinary Committee made its decision last Friday, following an adjournment of the case, which was initially heard in May of this year.
There were three heads of charge against Mr Hough:
The Committee found the majority of the first head of charge not proven, with the exception of the charges that Mr Hough failed to provide and ensure adequate overnight care for Mya and that it was inappropriate and unreasonable for him to plan for the wound management to be undertaken by Mya’s owners following the second procedure on 21 May 2014.
Regarding the second head of charge, the Committee found it proven that Mr Hough did fail to provide information about post-operative care and out-of-hours cover details to Mya’s owners. However it found Mr Hough’s failure to communicate with the owners regarding treatment options and to provide them with adequate information as to Mya’s post-operative condition not proven.
The third head of charge in its entirety was admitted and found proven.
The Committee also found that those charges that were found proven amounted to disgraceful conduct in a professional respect with the exception of Mr Hough’s failure to provide and/or ensure adequate overnight care and his failure to failure to provide out-of-hours details to Mya’s owners.
In deciding on an appropriate sanction, the Committee expressed significant concerns over Mr Hough’s treatment of Mya, in particular his "failure to devise and implement proper and sufficient procedures to ensure that this dog was not released to owners unless it was safe for her to be released and... that the owners were fully advised as to what was required of them."
The Committee felt that Mr Hough had given "insufficient attention" to Mya’s post-operative care but did accept that the conduct represented a single incident. During the course of the hearing the Committee also heard mitigating evidence given on behalf of Mr Hough, with a number of written testimonials as well as witness evidence in support of his clinical expertise and surgical skills.
The Committee accepted that Mr Hough had taken to heart the lessons to be learnt from the charges against him and had implemented a number of written protocols to prevent recurrence of the shortcomings in his treatment of Mya. Furthermore, the Committee also found that Mr Hough had demonstrated insight into the conduct found against him and that he had apologised for the disparaging remarks he made about other veterinary practitioners.
Alistair Barr, chairing the Disciplinary Committee and speaking on its behalf, said: "In short, the Committee is persuaded that Mr Hough has made a good start in putting in place systems to ensure that the interests and welfare of the animals treated at his practice surgeries are not discharged from care until they are fully ready to be discharged and that the owners of such animals will, in future, be fully informed of what might be asked and required of them when their animals are returned into their care after surgery."
He added: "There are no other areas of [Mr Hough’s] professional practices which appear to the Committee to call for improvements. Accordingly, the Committee is persuaded on this evidence that there is reason to believe that the lessons which Mr Hough needed to learn have been learnt and concludes, therefore, that the sanction of a formal and solemn reprimand adequately meets the needs of the public interest in, and requirements of, this particular case. Mya did make a full recovery from her extensive surgery but she and her owners deserved better post-surgery advice and support."
Enrolment is now open for the programme, which matches participants with an experienced supervisor and provides BSAVA support and guidance.
The Association says the qualification is intended to give veterinary surgeons the opportunity to investigate in more depth any aspect of clinical research relating to their work – in particular vets working in practice, including those who may be unsure how to take the first step.
It could be a special interest, such as evaluating risk factors for a particular disease or common case they see in practice, with experienced peers available in diverse areas – from exotics to ophthalmology and nutrition to internal medicine.
The Masters is a significant addition to the most successful CPD programme in the 60-year history of the BSAVA, spearheaded by Academic Director Frances Barr (pictured above right).
Frances said: "This qualification offers exciting possibilities for vets to unlock their inner researcher, finding answers to clinical questions faced in practice and guided every step of the way by highly experienced supervisors and the BSAVA team.
"It furthers the BSAVA’s mission to help vets realise their ambitions and develop through lifelong learning at every stage of their careers, which we hope will have a very positive impact on the profession."
The Masters programme, validated by Nottingham Trent University, is aimed at people who already have any accredited postgraduate certificate (60 credits at Level 7) relevant to some aspect of veterinary medicine or surgery.
It is based on a further 1,200 study hours and could be flexibly achieved in two years of part-time study or up to five years, depending on the project type and an individual’s availability. It starts with online study into the principles of clinical research, which students will then apply to their own research project.
The programme starts in January 2017 and applications are now open.
Students can enroll online and find out more information at www.bsava.com or by emailing masters@bsava.com.
Using 14 years’ of race day veterinary reports, the study found that soft tissue injuries, respiratory conditions and gait abnormalities were the most commonly reported issues. Soft tissue injuries include wounds and lacerations. Those classified as 'gait observations' primarily relate to horses reported as lame, moving poorly or being stiff, but without a specific cause being identified. The majority of horses with respiratory conditions had epistaxis.
Researchers say the findings will help prioritize efforts and direct research to identify risk factors for the most common and/or severe conditions, with the aim of developing strategies to further reduce injuries and fatalities in British flat racing, building on its already strong record on equine welfare.
Sarah Rosanowski, PhD PGDipVCS BSc, at the Royal Veterinary College said: "It was not surprising to find that most veterinary incidents reported on race-day are relatively minor and not career-ending. This is of course a good thing.
"Although the good news is that the majority of injuries are not life-threatening, the fatality rates in British flat racing have remained relatively stable rather than declining over the past decade.
"The ongoing surveillance by the British Horseracing Authority is important as it provides a way to track the occurrence of veterinary events over time. Now that we have a baseline against which to monitor the effects of future interventions, there will be opportunities to further improve horse welfare and racing safety."
Reference
Buprelieve is a 0.3mg/ml buprenorphine solution for injection, licensed for post-operative analgesia and to potentiate the sedative effects of other centrally-acting agents in dogs and horses. It can be administered by intramuscular or intravenous injection to dogs and cats and by intravenous injection to horses and is available in 10ml multi-dose glass vials.
Dr Rich Irvine BVSc MRCVS, veterinary services manager at Jurox (UK) Limited said: "We are delighted to be extending our range of products with the launch of Buprelieve which will provide veterinary practices with effective and economical analgesia.
"The launch of Buprelieve will be supported by our highly qualified team of veterinary surgeons who aim to deliver top quality help, advice and assistance for clinics wishing to perform best practice anaesthesia across all patient groups."
Jurox says it has been listening to the concerns of veterinary surgeons who say they want high quality generic medicines at affordable prices along with transparency as to what they are paying for each vial. As a result, the company says it is launching Buprelieve at a very affordable list price with a simple and generous introductory offer or rebate.
Richard Beckwith, country manager of Jurox (UK) Ltd, said: "Jurox prides itself on providing customers with a range of high quality medicines and we believe the launch of Buprelieve will also satisfy vets’ increasing requests for competitively priced products. We understand that providing high quality pain relief is critical and Buprelieve helps vets deliver the care they demand for their patients."
For more information, contact your local Jurox technical advisor, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
The letter outlines how the organisations want to work with the government to ensure the best possible outcome for animal health and welfare, public health and the veterinary profession post-Brexit, but also voices concern that perceptions of ‘anti-foreigner’ rhetoric may already be having an impact on the veterinary workforce.
Here is the full text of the letter sent to the Prime Minister on the afternoon of Tuesday 18 October 2016:
Dear Prime Minister,
Like all professions and sectors, we are currently involved in detailed debates regarding how Brexit is likely to affect our members and how we can best harness the opportunities it may present. We are very keen to work with the government to make a success of Brexit within our sector. The veterinary profession plays a crucial role in protecting public health, relies heavily on EU graduates and is already feeling the impact of the EU referendum.
The UK veterinary profession is made up of over 26,000 veterinary surgeons and over 11,000 veterinary nurses, working to improve the health and welfare of animals, to monitor and control the spread of diseases, and to assure the safety of the food we eat. Each year around 50% of veterinary surgeons registering to practise in the UK are from overseas, with the vast majority coming from the EU. EU veterinary surgeons make a particularly strong contribution to public health critical roles such as working in the Government Veterinary Services. In the meat hygiene sector some estimates suggest 95% of veterinary surgeons graduated overseas. Consequently, Brexit and accompanying changes to the mutual recognition system or immigration restrictions could have a profound impact upon the veterinary workforce.
We are currently considering how best to manage the potential impact on the veterinary workforce, and will be very pleased to discuss these issues with the relevant government departments in due course. However, even before Article 50 is triggered we are experiencing a negative impact on the existing veterinary workforce.
We have received reports that the increasing focus on foreign workers is causing personal distress to individual members of the veterinary profession who live and work in the UK. There are also reports of a negative impact on recruitment and retention: those involved in public health critical roles, such as meat hygiene, are having increasing difficulty recruiting much needed EU veterinary surgeons to work in the UK; leading experts from overseas are turning down employment offers from top UK universities; and many others are considering leaving the UK due to a feeling it is no longer welcoming to foreigners. There is a danger that the language and rhetoric around Brexit, alongside the ongoing uncertainty for non-British EU citizens, could seriously impact the veterinary profession’s ability to fulfil its essential roles.
The government has encouraged professions like ours to present factual data on the EU migration issues so that you can fully understand the challenges the country faces. The RCVS has begun the process of commissioning detailed research into the impact that Brexit is having upon those working in the profession and the implications this could have for the veterinary workforce. We will keep your officials informed as to the results of this research.
In the meantime, we reiterate our call for the government to protect the status of non-British EU vets and vet nurses currently working and studying in the UK, and urge Ministers to be mindful of the negative impact of what may be perceived as ‘anti-foreigner’ rhetoric.
We are committed to working with you to identify opportunities created by Brexit for animal health and welfare, public health and veterinary research and to realise our joint vision for the UK to continue to lead in these areas, and we are keen to maintain close communication with you and your colleagues as the negotiations develop.
Yours sincerely,
Chris Tufnell, President, Royal College of Veterinary SurgeonsGudrun Ravetz, President, British Veterinary Association
The nomination period runs up until 5pm on Tuesday 31 January 2017. In order to stand, candidates need to submit a nomination form, submit a short biography and personal statement and supply a high resolution digital photo.
Each candidate also needs two nominators who are veterinary surgeons on the College’s Register but who are not current RCVS Council members.
Dr Chris Tufnell, RCVS President, said: "As someone who has been a member of Council since 2009 I can honestly say that the discussions you have and the decisions you make through both Council and its various committees do have a tangible impact on the future of the profession.
"For example, in my relatively short time as a Council member I have been involved in the review of specialisation in the profession and the setting up of Advanced Practitioner status, the championing of primary care as a valuable discipline in its own right and overseen the delivery of an ambitious Strategic Plan through my position on the Operational Board.
"These are all areas that I never imagined I’d be able to influence from my position as a practising vet in general practice. So, if you are interested in having a say in issues as varied as CPD policy and how we respond to the challenges and opportunities of Brexit, then please put yourself forward for Council."
Prospective candidates are invited to attend a ‘Meet the RCVS Day’ at the College’s offices in Belgravia House, London, on Wednesday 23 November 2016 where they will have the opportunity to talk to RCVS President Chris Tufnell and find out more about the role of the College, its Councils and its committees.
Those interested in attending should contact Emma Lockley, RCVS Events Officer, on e.lockley@rcvs.org.uk or 020 7202 0773. Reasonable expenses for travel will be reimbursed.
The election period starts around mid-March and will run until 5pm on Friday 28 April 2017. Ballot papers will be sent to veterinary surgeons who are eligible to vote in the week commencing Monday 13 March 2017.
Nomination forms, guidance notes and frequently asked questions for prospective RCVS Council candidates can be found at www.rcvs.org.uk/rcvscouncil17.
Under the Petplan Portfolio Rewards scheme, each time a practice generates a full policy (including clients continuing cover from IVC /4 week free policies) they earn Portfolio Rewards credits.
A practice issuing Immediate Veterinary Cover (IVC) ordinarily earns 150 credits when the client continues their cover onto a full policy but, during this promotion, a full policy generated by an IVC will earn 300 credits, equivalent to £12.
Credits can then be exchanged against a range of products, from essential veterinary equipment and specialised literature to a variety of indulgences including chocolates and bottles of wine, leisure activities or team nights out.
Head of Sales & Partnerships at Petplan, James Barnes said: "Petplan is the UK’s no 1 pet insurance provider and our unique relationship with the veterinary profession remains an important part of our success so we wanted to do something extra to thank practices for their efforts promoting Petplan insurance to their clients during 2016. We know many practices like to exchange their Portfolio Rewards at Christmas so this promotion gives practices the chance to boost their account before the festive season."
For further information about the scheme or working with Petplan, visit petplanvet.co.uk.
BVA President Gudrun Ravetz said: "Veterinary View not only highlights some of the veterinary profession's fantastic work, but complements our joint project with RCVS, Vet Futures, in exploring how the profession can best shape its own future. We hope it will stimulate debate among vets, and the wider community in which we work, about both the big challenges and opportunities that the veterinary profession is facing."
The series includes a number of videos which showcase more recent industry developments:
Stem Cell therapy for the treatment of canine osteoarthritis (VetCell Therapeutics)
Pharmtrax, a mobile device for vets to record work and dispensing on the farm (Henry Schein Animal Health)
Hormone implants as an alternative to castration (Virbac Animal Health)
Practice management support from Zoetis
Preventing an epidemic of equine flu (Merial Animal Health)
Sileo provides a micro-dose of dexmedetomidine hydrochloride, a selective alpha-2 adrenoceptor agonist which Zoetis says helps a dog calm down or remain calm yet fully functional in situations involving fear-eliciting sounds.
Sileo is presented as an oromucosal gel formulation in a 3ml oral syringe that can be used to apply multiple doses.
Zoetis says that its user-friendly application means that, once prescribed, it can be given by the dog owner and used only when needed for each noise anxiety event. It takes effect within 15 - 60 minutes and last for 2-3 hours. Should the fear-eliciting noise continue, further doses can be given at two hour intervals up to a total of five times during each noise event.
The company says that even when the full dosing limit is used, the dog will remain functional during treatment; the clinical effects of dexmedetomidine are dose-dependent and the anxiolytic effect is reached before the sedative effect.
Animal behaviourist, Jon Bowen BVetMed DipAS (CABC) MRCVS, said: "Fear of seasonal loud noises such as fireworks, thunder and gunshots are known to affect around 50% of the UK dog population but the prevalence of fears of other everyday noises and the extent to which those fears contribute to nuisance and problem behaviour in dogs is something we are researching at the moment. Sileo is ideal as an acute anxiolytic for planned or expected events such as fireworks or thunder, but it has an even wider range of potential applications in planned events that involve stressful noise exposure including travel, social gatherings and even visits to the vet."
Sileo is available to order now via your veterinary wholesaler.
For more information contact your Zoetis account manager or customer support on 0854 300 8034 or visit www.zoetis.co.uk/Sileo.
Dan Forster MRCVS and his wife Kirsty, a veterinary nurse, run The Mobile Vet Ltd, which offers a 24/7 mobile service to clients and their animals on the Isle of Wight. The team work out of custom-designed vehicles, as well as their fully equipped static veterinary clinic in Newport.
In launching The Mobile Vet, their vision was to create a mobile clinic which could provide all of the services normally provided in a traditional clinic rather than just some. The veterinary team uses the latest technology and veterinary software to communicate with clients and works from vehicles specifically designed by Dan and Kirsty.
The Queen’s Awards for Enterprise are awarded to businesses for outstanding achievement in International Trade, Innovation and Sustainable Development. Winners of the Innovation Awards are judged to have shown outstanding success as the result of an innovation.
Dan said: "We aim to offer a caring and professional service to Islanders and their pets while also maintaining a good work/life balance. We can do almost everything from our vehicles but, when necessary, we utilise our fully equipped static clinic. We aim to offer a highly professional veterinary service using state-of-the-art equipment, which is also convenient to our clients. We have recently introduced a CT scanning service and laparoscopic surgery to expand our clinical services further.
"We are honoured to receive this prestigious award and had a fantastic day. The Award would never have been achievable without the support of our wonderful team. We look forward to continuing to provide an exemplary level of service to our clients."
The RVC is the oldest veterinary school in the English-speaking world, and the creation of the College in 1791 marked the establishment of the veterinary profession in Britain.
To mark its 225 years and celebrate the heritage of veterinary and scientific education, the RVC invited alumni back to attend a programme of events, including a gala dinner on Saturday and an Open Day and Campus Tour on Sunday.
Sunday’s activities included displays focusing on the history of the RVC, talks, a film screening and an ethical debate. The ethical debate related to the balance between business and welfare in all aspects of veterinary work. There were events for staff at both the Camden and Hertfordshire campuses on the Friday to mark the College’s birthday.
RVC Principal Stuart Reid said: "It is a great honour to lead the RVC, which has achieved so much over the centuries, within this era of so many exciting breakthroughs. The College has always looked beyond the horizon to make advancements in science and practice, for the benefit of patients and communities globally, yet it is crucial to also recognise the essential contributions of those who have gone before. The early pioneers and those who followed them played essential roles in the evolution of both veterinary and human medicine and the advancement of science.
"As we celebrate 225 years as a world-leading institution, we honour all who have worked and studied here through the centuries. Our current advances in knowledge are built on the efforts of all who have been part of the RVC through the centuries. By acknowledging this heritage, we also reflect on how efforts being made today by researchers, practitioners and students have long-term implications for animal health and welfare globally."
Equitop GLME is a palatable, pearl formulation joint supplement developed to support the healthy function of cartilage, joint capsules, tendons and ligaments. It is derived from an active extract of New Zealand Green Lip Mussels - a natural source of glucosaminoglycans (GAGs), chondroitin and essential fatty acids – and is tested free of prohibited substances.
Boehringer says the nutrients in Equitop GLME help to lubricate joints, as well as supporting normal joint function, the stability and elasticity of ligaments and the shock-absorbing properties of cartilage.
Equitop GLME is fed once a day either separately or mixed with feed and one tub will typically last for 30 days and can be used in all horses and ponies.
Dr Amy Scott, brand manager for Equitop GLME at Boehringer Ingelheim, said: "By encompassing Equitop GLME into the Equitop portfolio and launching easy-to-read new packaging, we are enhancing our product offering to both veterinary practices and horse owners."
For more information, contact your Boehringer account manager.
The initiative will run until early 2019, and has been expanded to include cats as well as dogs. In the run up, Lintbells is also offering lunch and learn sessions to help practices implement the clinics.
The company reports that feedback from 50 veterinary surgeons, nurses and practice managers who took part in the initiative last year was encouragingly positive. 86% agreed or strongly agreed that they are now managing mobility issues more effectively in practice and 90% thought client compliance had increased.
96% said they thought vets, nurses and reception staff were communicating more effectively. 95% thought the training had improved staff morale. 94% of veterinary staff felt clients were more confident about managing their pet’s condition and 92% thought more mobility issues had been identified. 74% said they thought practice revenue had increased.
Lintbells Brand Manager, Gemma Cunningham said: "We’re really pleased to be able to help practices to provide support for pets with stiff joints. This year we’ve made some exciting additions to the practice pack based on our ongoing conversations and feedback. Mobility issues in cats are often overlooked and we want to raise awareness and help support owners. By including cats this time round we hope to assist practices with their efforts to encourage cat owners to have their less active and sedentary cats checked out."
Practices that want to register an interest in receiving a Mobility Matters pack can contact their local Lintbells Veterinary Business Development Executive or visit www.lintbellsvet.com.
Eurican Herpes is used to vaccinate pregnant bitches to prevent mortality, clinical signs and lesions in puppies from canine herpes virus infections acquired in the first few days of life, through passive immunity. It is the only canine herpes vaccine.
Humphrey Grimmett, Business Head for the pet prescription portfolio at Boehringer Ingelheim said: “We do understand how disruptive and frustrating it is when vaccines such as Eurican Herpes aren’t available to veterinary practices.
“We would like to reassure veterinary practices that we are doing everything we can behind the scenes to re-establish supply of Eurican Herpes, and we thank them for their support and patience.”
For further information, contact Boehringer’s Technical Services Team on 01344 746957 or email vetenquiries@boehringer-ingelheim.com.
NOAH Chair Gaynor Hillier said: "The production and supply of veterinary medicines is totally dependent on complex international supply chains that must continue to function effectively after Brexit, their unique status being recognised in the recent government White Paper.
"Raw materials will need to arrive at manufacturing sites and veterinary medicines will need to be transported across borders to meet market requirements. Any border delays, additional complex processes or increased costs will risk medicines availability for UK vets, farmers and all our animals."
According to a recent NOAH member survey, less than 15% of companies say they are prepared for a 'hard Brexit' with the vast majority of respondents saying they are not fully prepared should there be a reversion to WTO rules on 30 March 2019.
NOAH says this is not through lack of effort or unawareness of the need to act, but due to the magnitude of the complex tasks involved in such a specialist sector, coupled with uncertainty over what a 'no-deal' Brexit will look like.
In contrast, almost 60% of companies said they are prepared for a transition period to December 2020. Even then, NOAH says the proposed transition period will not be enough in some cases.
The survey examined product availability in the UK: almost 55% of respondents reported potential availability issues for the UK market impacting more than 40% of their products. The full spectrum of types of products (from vaccines to painkillers: from antibiotics to wormers) across all animal species (farm, equine and pet) are potentially at risk, with particular concerns raised around the supply chain for vaccines.
EnteroZoo is a dietary supplement composed of organic mineral and purified water in a gel suspension. Enteromed says it works by binding bacterial toxins as it passes through the animal's digestive tract, thereby helping to maintain a healthy gut and intestinal balance.
Enteromed says that compared to old classic adsorbents, such as clay or charcoal, EnteroZoo can be used long-term and is gentle on an animal's intestines.
The company points to a new in-vitro study from Brighton University School of Pharmacy & Biomolecular Sciences which has shown that EnteroZoo adsorbs E. coli, Shigella and C. difficile toxins1 – common causes of gastrointestinal infection and diarrhoea.
EnteroZoo is suitable for all animals including pregnant and nursing females. It is tasteless and odourless and the company says animals generally accept it without any problems. It can be administered in various ways: directly into the mouth, mixed into feed, put on a treat, mixed in an appropriate amount of water or administered with a plastic syringe into the oral cavity.
For more information, contact: enterozoo@enteromed.co.uk, or visit: www.enterozoo.co.uk
Whilst the decision has been welcomed by the BVA and leading animal charities, it has not been entirely free of controversy. According to various reports, the Press Association has seen a letter from Defra to the Royal Veterinary College in February this year, which said the scientific studies it had commissioned were 'not strong enough to support a ban'.
Talking to the BBC, Ian Gregory, a lobbyist for pet collar manufacturers said that charities had also exaggerated the shock delivered by the collars, which at typically one millijoule is 1000 times less than cattle fencing. He argued that: "The anecdotal problems reported with pet collars can be resolved by product standards rather than by banning a proven technology".
The government has stopped short of banning invisible fencing systems which can keep pets away from roads, saying that the devices are particularly useful for cat owners and animals often respond well to invisible fencing and quickly learn to stay within a boundary without receiving a static pulse.
BVA President John Fishwick said: "As we review the latest evidence on the welfare impact of pulse pet containment fences, we would like to see them covered by a code of practice, as well as the regulation of the sale of these devices and manufacturer’s instructions, to ensure that the potential adverse effects of use are highlighted to animal owners and consumers."
Photo: Shutterstock
Dr Thomason initially denied both heads of charge, but on the third day of the hearing he changed his plea and admitted the charge in its entirety.
The first part of the charge related to the fact that the seller of the horse was a both a client of Dr Thomason’s practice and a personal friend of his, and he therefore had a potential and/or actual conflict of interest.
Dr Thomason did not disclose this professional and personal relationship to the prospective purchaser before the pre-purchase exam.
The prospective purchaser only discovered Dr Thomason’s relationship with the seller when reading the vetting certificate at home, and stated that, in the past, she had had a similar experience in which the horse was then found to be lame. She later found out the extent of the personal relationship, when invited to join the seller on a social media site.
The Committee found that, in this set of circumstances, Dr Thomason should not have undertaken the pre-purchase exam at all, and, at the very least, disclosed his personal and professional relationship with the vendor.
The Committee also found that although Dr Thomason did have a system in place to inform any prospective purchasers if the vendor was a client of his practice, this failed to work on this occasion and neither the practice nor Dr Thomason told the prospective buyer that the seller was a client before booking the pre-purchase exam. Dr Thomason had no similar system in place to disclose any close friendships with sellers.
Dr Thomason did not consider there was a conflict of interest as he felt confident he could carry out the pre-purchase exam impartially. In addition, it was his belief that the seller had been alerted to the conflict through a system in place at his practice, implemented to safeguard against this type of error. He stated that he in no way attempted to hide his relationship with the seller to the prospective purchaser.
It was not alleged that Dr Thomason had acted dishonestly.
Ultimately, the Committee found Dr Thomason not guilty of disgraceful conduct in a professional respect.
Ian Green, chairing the Committee and speaking on its behalf, said: "Whilst the Committee concluded that the respondent’s view of his obligations to disclose both the professional and personal relationships he had with the vendor was mistaken, it did not find any improper motivation on his part. It has already noted that he sought to disclose to the prospective purchaser through his system the fact that the vendor was a professional client of his.
"The Committee has weighed all these matters very carefully. It is for the client to determine whether or not to proceed with a PPE when in possession of all relevant facts in relation to any potential conflict of interest, and not for the veterinary surgeon to decide. The autonomy of the client must be respected. The Committee was firmly of the opinion that a failure to comply with the Code is very serious. However, taking into account the particulars of this case, the Committee does not consider that the actions of the respondent amount to disgraceful conduct in a professional respect."
The extension includes a new diagnostic imaging suite with both CT and MRI scanners, a fourth operating theatre, two more consulting rooms, an additional ward for dogs and an expanded office for clinicians.
North Downs hospital director Terry Emmerson said: "This significant investment illustrates our commitment to providing the highest standards of medical and surgical care for our pets in a caring, compassionate environment.
"It has provided us with a number of important new facilities, allowing us to continue to build on our services and our level of care.
As part of the expansion, North Downs has also recruited five more clinicians, two specialising in small animal surgery, one in neurology, one in ophthalmology and one in anaesthesia.
Mr Emmerson said: "All the investment in facilities and technology is very important and exciting but we also recognised the need to invest in recruiting more talented staff to help us make the most of it all.
"That’s why we have added five new clinicians in several key disciplines and in turn increased the size of our clinicians’ office to help incorporate those additional staff.
"It all means we can now offer an even better service, leading facilities and treatment within a far more structured and organised layout which helps makes everything more efficient and user-friendly for staff and patients."
For more information about North Downs Specialist Referrals, visit www.ndsr.co.uk.
Moxiclear contains moxidectin and imidacloprid.
In dogs, Moxiclear can be used for the treatment and prevention of flea infestations and as part of a treatment plan for flea allergic dermatitis. It is also indicated for lungworm, ear mites, sarcoptes mites, biting lice, round worm, hookworm, whipworm, skinworm, and prevents heartworm.
In cats, Moxiclear can be used for the treatment and prevention of flea infestation and flea allergic dermatitis, as well as ear mite infestations. It is also indicated for notoedric mange, gastrointestinal nematodes; whipworm, roundworm and hookworm, and for the prevention of heartworm disease.
In ferrets, Moxiclear can be used to treat and prevent flea infestation, and prevent heartworm.
Moxiclear is available for 4kg-40kg dogs, with four pipette fill sizes. Small cats and ferrets weighing less than 4kg are catered for with a 0.4ml pipette. Large cats weighing 4-8kg can be treated with the Moxiclear 0.8ml pipette.
Lorron Bright, Norbrook Product Manager, said: "Moxiclear offers good value, broad-spectrum parasite control for dogs, cats and ferrets. This latest launch provides our customers with an excellent value, alternative choice for a imidacloprid/moxidectin product."
Richard Palmer, Norbrook Global Head of Sales and Marketing, said: "Moxiclear spot-on is the 11th product we have launched in the past three years. Six of the new products are in the companion animal sector as we continue to strengthen our foothold in the growing global companion animal market. Norbrook is committed to delivering a strong new product pipeline, along with our multi-year £50 million investment programme."
Carl's article: 'Are you using a safety checklist in your practice?', focuses on the benefits of introducing a safety checklist in practice to reduce patient morbidity, mortality and to improve communication between members of the veterinary team.
He explains how a checklist helps eliminate the need to memorise every single step of a protocol and self-limit any errors that may eventually lead to a fatal or near-fatal incident, and how it should contain a limited number of elements, allow quick completion and most importantly be relevant to the situation.
The article includes information on how to introduce a safety checklist, steps to consider and how to use one in practice.
It also contains links to downloadable tools including the Association of Veterinary Anaesthetists (AVA) safety checklist and implementation booklet and information on the association’s ‘Safer Anaesthesia Project’. An editable safety checklist will also be available to download from the ‘Anaesthesia1ST’ blog that practices can adapt to their own requirements.
Richard Beckwith, country manager of Jurox (UK) said: "Our hugely popular Anaesthesia1ST newsletter features state-of-the-art, practical and easy to read articles to help veterinary professionals deliver 1ST class anaesthesia to all patients. Our latest edition will challenge practices to consider safety checklists as an essential part of their pre-anaesthetic routine in order to reduce the risk of mistakes."
To sign up to the Anaesthesia1ST newsletter visit the Alfaxan website – www.alfaxan.co.uk, contact your local Jurox technical sales representative or email Jurox at info@jurox.co.uk.
Alexander Reiter and Margherita Gracis formed the new editorial team and selected an international collection of leaders in their fields of expertise to contribute to this latest edition.
Alexander said: "This is a timely publication, as veterinary dentistry is a field that continues to grow in importance for the general veterinary practitioner. We found it important to add 'Oral Surgery' to this new edition, as many procedures performed in and around the mouth involve surgical techniques."
The BSAVA Manual of Canine and Feline Dentistry and Oral Surgery, 4th edition, is an accessible source of core information for general small animal veterinary surgeons, nurses/technicians and students interested in developing their theoretical knowledge and practical skills in dentistry and oral surgery.
The manual is now available from the BSAVA website (www.bsava.com/shop), the BSAVA Library (www.bsavalibrary.com/manuals), or by phone: 01452 726700.
The aim of the competition is to highlight top tips for pet owners and the benefits of building a den to help calm and reassure dogs during the fireworks festivities.
Practices that want to take part in the in the competition need to post pictures of their dens and waiting rooms on the Ceva Animal Health Facebook page in October. The winning practice will receive a £200 voucher and there are 10 runner up prizes of luxury chocolate hampers.
Abigail King, behaviour product manager at Ceva Animal Health, said: "Our hugely popular fireworks display competition encourages veterinary practices to create eye-catching and imaginative displays that help educate pet owners on what can be done at home to help calm and reassure pets with firework fears."
Ceva has a range of marketing materials for veterinary practices to use in the competition, including waiting room materials.
For further information, contact your Ceva territory manager.
Working in collaboration with researchers at University of Texas, Southwestern (UTSW) Medical Center, the team has succeeded in using gene editing techniques on dogs to restore the expression of the dystrophin protein that is absent in DMD patients’ muscles to levels that could be life changing.
DMD is the most common, fatal, genetic disease that affects children. The same disorder also occurs in many dog breeds. It is caused by mutations in the gene that encodes dystrophin, a crucial protein that helps protect muscle fibres and the heart when they contract. Patients with the disease produce effectively no dystrophin protein, so their muscles and heart become damaged during contraction, leading to inability to walk, skeletal deformities, breathing problems and heart failure. Patients with DMD have a life expectancy that does not go far beyond their twenties.
Researchers say that this preliminary research, published in Science, demonstrates an approach that could lead to an effective, in principle one-time treatment for DMD for the most common genetic mutations affecting human patients. Through a single intravenous injection, researchers have been able to modify the dystrophin gene in many muscles of the body, including the heart, with the result that some muscles now had almost the normal amounts of dystrophin protein.
The team, led by Eric Olson, Ph.D., professor and chair of the Department of Molecular Biology at UTSW Medical Center and founder and chief science advisor of Exonics Therapeutics, and Richard Piercy, Ph.D., MRCVS, Professor of Comparative Neuromuscular Disease at the RVC, identified a naturally-occurring mutation in the dystrophin gene in a dog brought to the RVC’s Small Animal Referral Hospital.
Working now with relatives of this first dog, the combined group has used a technique called ‘SingleCut CRISPR gene editing’, where the researchers target a specific region of the subject’s own DNA. Harmless viruses encoding the gene-editing protein CRISPR/Cas9 were used to express the enzyme in muscle to cut the dogs’ own DNA at a precise location in the dystrophin gene through use of a molecular guide. The body’s own processes then repair the cut, which results in removing the negative effects of the existing mutation.
The researchers have demonstrated that dogs treated in this way had restored ability to produce large amounts of the dystrophin protein in their muscles and heart, and in the dog with the highest dose, cardiac muscles were found to have restored dystrophin protein to up to 92% of normal amounts after the single treatment.
The team believes this is the first time that this form of gene editing therapy has been conducted after birth in an animal larger than a rodent. With further longer-term research, efficacy and safety testing, it is hoped that this breakthrough will have human application. This treatment may be a significant step toward developing a gene editing therapy to repair genetic mutations for DMD, as well as a range of diseases caused by genetic mutations.
Richard Piercy, Professor of Comparative Neuromuscular Disease at the RVC, said: "Researchers have been looking for an effective and durable treatment for Duchenne muscular dystrophy for many years. This SingleCut gene editing approach, pioneered by Dr. Eric Olson’s group, has the potential to be a one-time treatment that could restore dystrophin protein. It is hugely exciting that through a single intravenous injection we’ve been able successfully to modify the dogs’ own DNA so they start generating dystrophin protein again. There is more work to be done, but with this exciting breakthrough, we feel we are a significant step closer to finding an effective treatment.
"A great many genetic diseases affect humans, dogs and other species - many, like DMD - with tragic consequences and this form of gene editing treatment might well be applicable in many of them. We’re hopeful that we’re paving the way for future research into treating some of the most serious genetic conditions that affect us today."
The online seminar, which equates to one hour’s CPD, features six UK experts in equine endocrinology, with the objective of supporting equine and mixed practice vets in using the clinical history to guide their interpretation of the basal ACTH test results and subsequent treatment decisions.
The speakers participating in the Equine Endocrine Pioneers Circle are:
Harry Carslake MA VetMB DipACVIM MRCVS: Senior lecturer in equine medicine at the University of Liverpool
Edd Knowles MA VetMB MVetMed DipECEIM MRCVS: Specialist in Equine internal medicine at Bell Equine Veterinary clinic
Professor Cathy McGowan BVSc DipVetClinStud MACVSc PhD DEIM DipECEIM FHEA MRCVS: Head of Department of Equine Clinical Science and Director of Veterinary Postgraduate Education at the University of Liverpool
Dr Nicola Menzies-Gow MA VetMB PhD DipECEIM Cert EM(Int Med) MRCVS: Reader in equine medicine at the Royal Veterinary College
Victoria South MA VetMB CertAVP(EM) DipECEIM MRCVS: Senior assistant at Liphook Equine Hospital
Nicola Steele BVM&S CertAVP(EM) MRCVS: Fyrnwy Equine Clinic and Director of Veterinary CPD (Equine and Large Animal)
The webinar considers when vets should test for PPID and decision-making on the best test to use, how to interpret grey zone results and also how to interpret problematic follow up tests. The experts have different opinions on some of these areas, allowing vets in practice to see the different ways in which cases can be viewed and managed.
These principles are then reinforced by the use of three clinical case scenarios with the patients all having the same basal ACTH result but a different selection of clinical signs.
Liz Barrett, equine business head at Boehringer Ingelheim said: "Since the launch of our Talk About Laminitis initiative in 2012, more than 50,000 horses have benefited from complimentary basal ACTH tests to aid the diagnosis of PPID, however two common areas of uncertainty in interpreting ACTH results still exist. Firstly, the interpretation of borderline, equivocal or ‘grey-zone’ results and when PPID treatment should or shouldn’t be recommended and secondly, the interpretation of follow-up ACTH test results and when to advise altering the treatment dose.
"The Equine Endocrine Pioneers Circle webinar allows vets to update their knowledge on this broad subject area and illustrates that there is often more than one way to approach the diagnosis, treatment and management of the PPID case."
To view the Equine Endocrine Pioneers Circle webinar on the Boehringer Academy visit https://www.boehringer-academy.co.uk/webinar/bil205